|PROJECT TITLE||THE ‘RAPID INTERVENTION WITH GLYCERYL TRINITRATE IN HYPERTENSIVE STROKE TRIAL-2’ (RIGHT-2)|
|Funding body||British Heart Foundation Clinical Study CS/14/4/30972.|
|Overarching aim||The aim of the RIGHT2 trial is to assess the safety and efficacy of transdermal glyceryl trinitrate, a nitric oxide donor, in hyper-acute stroke in the context of a multicentre ambulance-based trial.|
|Methods||Randomised controlled clinical trial|
|The most important expected outcomes of RIGHT2 will be to determine the difference between GTN and no GTN in death, disability, dependency, mood, cognition, and quality of life following stroke.|
Peer reviewed publications and presentations at national and conferences.
Clinical-medical: a novel treatment for hyper-acute stroke which, if shown to be effective, will change management of stroke worldwide.
Economic: reduction in costs of hospital treatment and long term health and social care from stroke.
Social: prevention of long-term disability and suffering from stroke.